COVID-19 对前列腺癌咨询和治疗时间的影响。

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2024-12-01 Epub Date: 2024-05-07 DOI:10.1080/13685538.2024.2347465

Dejan K Filipas, Randi M Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A Ludwig, Hans Heinzer, Thomas Steuber

{"title":"COVID-19 对前列腺癌咨询和治疗时间的影响。","authors":"Dejan K Filipas, Randi M Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A Ludwig, Hans Heinzer, Thomas Steuber","doi":"10.1080/13685538.2024.2347465","DOIUrl":null,"url":null,"abstract":"Purpose: This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a \"minimal contact concept,\" which postponed clinical examinations until the day of admission.Methods: We analyzed patient data from a tertiary care center from 2018 to September 2021. The focus was on comparing the time intervals from ID to TC and from ID to RP before and during the CP.Results: Of 12,255 patients, 6,073 (61.6%) were treated before and 3,791 (38.4%) during the CP. The median time from ID to TC reduced from 37 days (IQR: 21 - 58d) pre-CP to 32 days (IQR: 20 - 50d) during CP (p < 0.001). Similarly, the time from ID to RP decreased from 98 days (IQR: 70 - 141d) to 75 days (IQR: 55 - 108d; p < 0.001) during the CP. There was a significant decrease in low-risk tumor cases at ID (18.9% vs. 21.4%; p = 0.003) and post-RP (4% vs. 6.7%; p < 0.001) during the CP.Conclusion: Our findings suggest that the COVID-19 pandemic facilitated more timely treatment of prostate cancer, suggesting potential benefits for both low-risk and aggressive tumor management through expedited clinical procedures.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of COVID-19 on the time to counseling and treatment of prostate cancer.\",\"authors\":\"Dejan K Filipas, Randi M Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A Ludwig, Hans Heinzer, Thomas Steuber\",\"doi\":\"10.1080/13685538.2024.2347465\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a \\\"minimal contact concept,\\\" which postponed clinical examinations until the day of admission.Methods: We analyzed patient data from a tertiary care center from 2018 to September 2021. The focus was on comparing the time intervals from ID to TC and from ID to RP before and during the CP.Results: Of 12,255 patients, 6,073 (61.6%) were treated before and 3,791 (38.4%) during the CP. The median time from ID to TC reduced from 37 days (IQR: 21 - 58d) pre-CP to 32 days (IQR: 20 - 50d) during CP (p < 0.001). Similarly, the time from ID to RP decreased from 98 days (IQR: 70 - 141d) to 75 days (IQR: 55 - 108d; p < 0.001) during the CP. There was a significant decrease in low-risk tumor cases at ID (18.9% vs. 21.4%; p = 0.003) and post-RP (4% vs. 6.7%; p < 0.001) during the CP.Conclusion: Our findings suggest that the COVID-19 pandemic facilitated more timely treatment of prostate cancer, suggesting potential benefits for both low-risk and aggressive tumor management through expedited clinical procedures.\",\"PeriodicalId\":55542,\"journal\":{\"name\":\"Aging Male\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aging Male\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13685538.2024.2347465\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2024.2347465","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究探讨了COVID-19大流行（CP）如何影响前列腺癌初步诊断（ID）与随后的治疗会诊（TC）或根治性前列腺切除术（RP）之间的时间线，原因是实施了 "最小接触概念"，将临床检查推迟到入院当天：我们分析了一家三级医疗中心从2018年至2021年9月的患者数据。重点比较了CP之前和CP期间从ID到TC以及从ID到RP的时间间隔：在12255名患者中，6073人（61.6%）在CP前接受了治疗，3791人（38.4%）在CP期间接受了治疗。从 ID 到 TC 的中位时间从 CP 前的 37 天（IQR：21 - 58d）缩短到 CP 期间的 32 天（IQR：20 - 50d）（p p = 0.003）和 RP 后（4% vs. 6.7%；p 结论：我们的研究结果表明，COVID-19 大流行有助于更及时地治疗前列腺癌，这表明通过加快临床程序对低风险和侵袭性肿瘤管理都有潜在益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of COVID-19 on the time to counseling and treatment of prostate cancer.

Purpose: This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a "minimal contact concept," which postponed clinical examinations until the day of admission.

Methods: We analyzed patient data from a tertiary care center from 2018 to September 2021. The focus was on comparing the time intervals from ID to TC and from ID to RP before and during the CP.

Results: Of 12,255 patients, 6,073 (61.6%) were treated before and 3,791 (38.4%) during the CP. The median time from ID to TC reduced from 37 days (IQR: 21 - 58d) pre-CP to 32 days (IQR: 20 - 50d) during CP (p < 0.001). Similarly, the time from ID to RP decreased from 98 days (IQR: 70 - 141d) to 75 days (IQR: 55 - 108d; p < 0.001) during the CP. There was a significant decrease in low-risk tumor cases at ID (18.9% vs. 21.4%; p = 0.003) and post-RP (4% vs. 6.7%; p < 0.001) during the CP.

Conclusion: Our findings suggest that the COVID-19 pandemic facilitated more timely treatment of prostate cancer, suggesting potential benefits for both low-risk and aggressive tumor management through expedited clinical procedures.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.